Morse Asset Management Inc acquired a new position in Haemonetics Co. (NYSE:HAE) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 10,880 shares of the medical instruments supplier’s stock, valued at approximately $1,309,000.

A number of other hedge funds also recently bought and sold shares of HAE. BlackRock Inc. raised its position in shares of Haemonetics by 5.9% during the 1st quarter. BlackRock Inc. now owns 6,385,237 shares of the medical instruments supplier’s stock valued at $558,580,000 after acquiring an additional 358,431 shares during the last quarter. Jackson Square Partners LLC grew its holdings in shares of Haemonetics by 12.8% in the 1st quarter. Jackson Square Partners LLC now owns 1,655,676 shares of the medical instruments supplier’s stock valued at $144,838,000 after buying an additional 187,950 shares during the period. Neuberger Berman Group LLC grew its holdings in shares of Haemonetics by 14.2% in the 1st quarter. Neuberger Berman Group LLC now owns 1,625,242 shares of the medical instruments supplier’s stock valued at $142,176,000 after buying an additional 202,406 shares during the period. Wells Fargo & Company MN grew its holdings in shares of Haemonetics by 6.9% in the 1st quarter. Wells Fargo & Company MN now owns 959,681 shares of the medical instruments supplier’s stock valued at $83,953,000 after buying an additional 62,238 shares during the period. Finally, Westfield Capital Management Co. LP grew its holdings in shares of Haemonetics by 2.7% in the 1st quarter. Westfield Capital Management Co. LP now owns 728,979 shares of the medical instruments supplier’s stock valued at $63,771,000 after buying an additional 19,027 shares during the period. Hedge funds and other institutional investors own 98.47% of the company’s stock.

HAE has been the subject of several research analyst reports. Morgan Stanley boosted their price target on shares of Haemonetics from $128.00 to $148.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Jefferies Financial Group upped their target price on shares of Haemonetics from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. JMP Securities upped their target price on shares of Haemonetics to $145.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 7th. TheStreet raised shares of Haemonetics from a “c+” rating to a “b-” rating in a research note on Tuesday, May 7th. Finally, Raymond James upped their target price on shares of Haemonetics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Haemonetics currently has a consensus rating of “Buy” and a consensus target price of $140.67.

Shares of HAE stock traded up $4.24 on Tuesday, reaching $137.41. The stock had a trading volume of 249,785 shares, compared to its average volume of 358,368. The company has a quick ratio of 1.34, a current ratio of 2.10 and a debt-to-equity ratio of 0.54. The stock’s 50-day moving average price is $122.92. The stock has a market capitalization of $6.75 billion, a price-to-earnings ratio of 57.49, a price-to-earnings-growth ratio of 3.26 and a beta of 0.82. Haemonetics Co. has a 12 month low of $80.24 and a 12 month high of $135.28.

Haemonetics (NYSE:HAE) last issued its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.81 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.18. The company had revenue of $238.50 million for the quarter, compared to analysts’ expectations of $236.82 million. Haemonetics had a net margin of 5.05% and a return on equity of 21.07%. Haemonetics’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.59 EPS. Research analysts forecast that Haemonetics Co. will post 3.03 earnings per share for the current year.

In other Haemonetics news, CEO Christopher Simon sold 24,412 shares of the stock in a transaction dated Thursday, May 23rd. The shares were sold at an average price of $99.39, for a total value of $2,426,308.68. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO William P. Mr. Burke sold 411 shares of the stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $103.38, for a total transaction of $42,489.18. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 48,830 shares of company stock worth $5,153,165. 1.32% of the stock is owned by insiders.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Recommended Story: What is Liquidity?

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.